Gilead?s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI

GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. All other trademarks are the property of their respective owners.
For more information about Gilead, please visit the company?s website at?www.gilead.com, follow Gilead on Twitter?(@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on?businesswire.com:?https://www.businesswire.com/news/home/20210309005909/en/
Jacquie Ross, Investors (408) 656-8793 Brian Plummer, Media (202) 309-5207 Source: Gilead Sciences, Inc.